BGLC vs IR · rev $9.5M vs P/E 49, rev $3.90B
BioNexus Gene Lab Corp Common stock (BGLC) versus Ingersoll Rand Inc (IR) — a side-by-side from cached financials, not a winner call.
BioNexus Gene Lab Corp Common stock (BGLC) is a specialty chemicals company listed on NASDAQ.
Ingersoll Rand Inc (IR) is a specialty industrial machinery company listed on US.
Latest reported BGLC revenue for 2024-12-31 was $9.5M. Net income was $1.6M. Revenue was down 2.7% from 2023-12-31 to 2024-12-31. BGLC currently screens at market cap $6.1M.
Latest reported IR revenue for 2026-06-30 was $3.90B. Net income was $448.9M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
BGLC currently screens at market cap $6.1M. IR currently screens at market cap $28.27B and trailing P/E 48.8.
Not investment advice. Open the BGLC and IR stock pages for the full models.
Not investment advice.